{"id":"NCT01875367","sponsor":"Spanish Breast Cancer Research Group","briefTitle":"Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer","officialTitle":"Phase III Trial to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous (IV) Administration in HER2 Positive Advanced Breast Cancer Who Have Received IV Trastuzumab at Least 4 Months and Without Disease Progression","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-09-18","primaryCompletion":"2016-11-30","completion":"2018-04-30","firstPosted":"2013-06-11","resultsPosted":"2021-02-01","lastUpdate":"2023-04-05"},"enrollment":166,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"Trastuzumab Injectable Solution","otherNames":["Herceptin"]},{"type":"DRUG","name":"Trastuzumab Injectable Product","otherNames":["Herceptin"]},{"type":"DRUG","name":"Trastuzumab Injection","otherNames":["Herceptin"]}],"arms":[{"label":"Arm A: T-IV + T-SC vial + T-SC device","type":"EXPERIMENTAL"},{"label":"Arm B: T-IV + T-SC device + T-SC vial","type":"EXPERIMENTAL"}],"summary":"GEICAM/2012-07 is a study phase III, prospective, open, randomized, multicenter and national designed to assess patient preference for intravenous (IV) or subcutaneous (SC) of trastuzumab, and within the SC by the administration through the vial or device self-administration in patients with disseminated breast cancer HER2.","primaryOutcome":{"measure":"Percentage of Participants With Subcutaneous vs. Intravenous Treatment Preference","timeFrame":"Up to 12 weeks","effectByArm":[{"arm":"Arm A: T-IV + T-SC Vial + T-SC Device","deltaMin":66,"sd":null},{"arm":"Arm B: T-IV + T-SC Device + T-SC Vial","deltaMin":71,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":10},"locations":{"siteCount":27,"countries":["Spain"]},"refs":{"pmids":["32578279"],"seeAlso":["http://www.geicam.org"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":81},"commonTop":["Anemia","Aspartate aminotransferase increased","White blood cells decreased","Creatinine increased","Alkaline phosphatase increased"]}}